Chinese pharma company focused on central-nervous-system (CNS) drugs, including antidepressants and antipsychotics.
Chinese pharma company focused on central-nervous-system (CNS) drugs, including antidepressants and antipsychotics.
Sells prescription drugs for the nervous system through hospitals, where government group-purchasing programmes press prices on older generics. Chinese rules restrict production of many psychotropic and anaesthetic drugs to licensed makers, which limits the number of competitors in parts of its range.
Moat: narrow (regulatory licence, brand). Established CNS drug portfolio and physician relationships in a specialized therapeutic area.
Headquarters: Taizhou, Jiangsu, China · Employees: 6,003
Size Jiangsu Nhwa Pharmaceutical (002262.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.48B, the 702nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥22.80 on 18 Nov 2026.
Performance Over six months the shares gained 8.1%, against +3.4% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 3.2% over the last twelve months (peer median +9.4%); the operating margin is 18.9% (peer median 10.1%).
Valuation It trades at 19.6× forward earnings against a peer median of 16.8× (6th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 15.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.22B | CN¥5.85B | CN¥5.63B | CN¥4.99B | CN¥4.25B |
| Revenue growth | — | +4% | +13% | +17% | — |
| Gross profit | CN¥4.38B | CN¥4.04B | CN¥3.99B | CN¥3.53B | CN¥3.16B |
| EBITDA | n/a | CN¥1.36B | CN¥1.45B | CN¥1.24B | CN¥1.05B |
| Net income | CN¥1.10B | CN¥1.06B | CN¥1.14B | CN¥1.04B | CN¥901M |
| Free cash flow | CN¥579M | CN¥687M | CN¥512M | CN¥677M | CN¥566M |
| Capital expenditure | CN¥490M | CN¥437M | CN¥450M | CN¥374M | CN¥328M |
| Total debt | CN¥392M | CN¥448M | CN¥449M | CN¥173M | CN¥122M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jiangsu Nhwa Pharmaceutical 002262.SZ | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Luye Pharma 2186.HK | $736M | -32% | +3% | 18% | 7.1× | -11.8% |
| Otsuka Hldgs 4578.T | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002262.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.0% | +2.6% | 10th highest of 21 |
| 6-month return | +8.1% | +3.4% | 10th highest of 20 |
| Distance from 52-week high | -11.3% | -22.7% | 5th highest of 21 |
| Revenue growth (TTM) | +3.2% | +9.4% | 6th lowest of 18 |
| Operating margin | 18.9% | 10.1% | 4th highest of 16 |
| Forward P/E | 19.6× | 16.8× | 6th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | -2.1% | 0.6% | 6th least demanding of 11 |
| Growth delivered (Del g) | +12.0% | +5.6% | 3rd highest of 11 |
| Hurdle (Req g minus delivered) | -14.1 pp | -10.8 pp | 4th least demanding of 11 |
| ROIC minus cost of capital | +15.9 pp | +3.7 pp | highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |